Logo_final_color.png
Cybrexa Therapeutics Expands Scientific Advisory Board With Appointment of Leader in Lung Cancer Research Roy Herbst, M.D., Ph.D.
August 03, 2020 07:00 ET | Cybrexa Therapeutics
NEW HAVEN, Conn., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ tumor targeting...
Logo_final_color.png
Cybrexa Therapeutics Completes Successful Pre-IND Meeting With FDA for CBX-12 (alphalex™-exatecan), a Novel Treatment for Solid Tumors
July 07, 2020 07:00 ET | Cybrexa Therapeutics
NEW HAVEN, Conn., July 07, 2020 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ tumor targeting...
Oncotelic Logo.png
Mateon Provides Update on its R&D Effort Against COVID-19
April 30, 2020 06:00 ET | Mateon Therapeutics
AGOURA HILLS, Calif., April 30, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics Inc. (OTCQB:MATN) report several peer-reviewed publications derived from its R&D effort against COVID-19. Published...
Oncotelic Logo.png
Mateon Announces the Filing of an IND with US FDA to Evaluate its Antisense Drug Candidate OT-101 in COVID-19 patients
April 27, 2020 08:00 ET | Mateon Therapeutics
AGOURA HILLS, Calif., April 27, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics Inc. (OTCQB:MATN) announced today it has submitted an Investigational New Drug (IND) application to the US Food and Drug...
red.jpg
IND for COVID-19 with Opaganib Submitted to the FDA by RedHill Biopharma
April 17, 2020 13:26 ET | RedHill Biopharma Ltd.
Proposed study intended to evaluate the safety and efficacy of opaganib in up to 60 patients hospitalized with positive SARS-CoV-2 infection and pneumonia in the U.S.--Opaganib’s unique mechanism of...
7 Hills Logo.png
7 Hills Pharma Announces FDA Clearance of Investigational New Drug Application for 7HP349, a First-in-Class Immune Stimulant 
April 14, 2020 08:00 ET | 7 Hills Pharma
HOUSTON, April 14, 2020 (GLOBE NEWSWIRE) -- 7 Hills Pharma, a clinical stage immunotherapy company focused on the development of drugs for treatment and prevention of cancer and infectious diseases,...
Q2Earth-logo.jpg
Q2Earth Signs Exclusive Option Agreement to License Promising Drug to Treat Bone Cancer in Children
January 22, 2020 09:00 ET | Q2Earth, Inc
Palm Beach, FL, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Q2Earth, Inc. (OTCQB: QPWR) (the “Company” or “Q2”) announced today that it has signed an Exclusive Dealing Option Agreement to provide the Company...
LogicBio-logo-RGB.png
LogicBio Therapeutics Announces Submission of Investigational New Drug Application (IND) for LB-001 for Methylmalonic Acidemia (MMA) and Highlights Key Corporate Milestones
January 10, 2020 07:05 ET | LogicBio Therapeutics
– Filed IND for lead GeneRide™ candidate LB-001 in pediatric MMA patients –– Phase 1/2 trial initiation planned for H1 2020, with preliminary data in H2 2020 –– Established research collaboration with...
2019 logo_150x35_jpg.jpg
Novan Further Expands its Proprietary Nitric Oxide Platform
October 18, 2019 08:30 ET | Novan, Inc.
A new product candidate, SB207, to target anti-viral opportunitiesPre-IND meeting anticipated in December 2019Development of SB207 to be focused on indications with unmet patient need, such as...
1555102157573_5c7ea78883c747000486abc8_logo.jpg
Qrons Appoints Veteran U.S. Based Biotech Executive Dr. John N. Bonfiglio to Lead IND and Capital Markets Related Activities
June 27, 2019 09:00 ET | Qrons Inc.
New York, NY, June 27, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Qrons Inc. (OTC: QRON), an emerging biotechnology company developing advanced stem cell-synthetic hydrogel-based solutions for the...